BridgeBio Receives Almost 300 Million for Continued Rare Disease Research

About BridgeBio Pharma

BridgeBio Pharmaceuticals was created in 2015 by veterans from the fields of academia and biotechnology. The company focuses on the development of new therapeutic treatments for genetic diseases.

BridgeBio has more than 15 ongoing projects. Four of these are currently in or approaching pivotal clinical trials. Ultimately, their aim is to support patients by translating scientific discoveries into therapeutics which can target the genetic cause of diseases.

While genetically based however, the company’s assets span many therapeutic areas. These include-

  • Endocrinology
  • Neurology
  • Renal Disease
  • Ophthalmology
  • Cardiology
  • Oncology
  • Dermatology

Some of the conditions they are currently working with are-

The Goal

There are more than 7,000 genetic diseases documented. They are caused by either mutations which are inherited by a parent, or by de novo mutations. Many rare diseases and cancers fall into this category. In total, genetic conditions affect between 25 and 30 million people in the United States alone. However, there are currently fewer than 500 therapies approved to treat these conditions.

It is clear that genetic diseases have a high unmet need. BridgeBio’s goal is to provide more patients suffering from these conditions with a therapeutic option.

New Funding

Thankfully, BridgeBio has just announced that they have received a new round of financing from their investors. This amount totals 299.2 million dollars. It will support not only the company’s current research for genetic conditions, but will help them to develop new programs as well.

They hope to expand their number of current projects, with the goal of getting more effective therapies into the hands of patients faster.

It takes not only vision, commitment, and dedicated research to accomplish this, but also financial support. Thanks to continued investment, BridgeBio is confident in their ability to make an impact on this patient community.

You can read more about BridgeBio’s work here.

Follow us